Voyager Reports $119.7M Net Loss, 41% Workforce Cut in FY25 Results
VYGR sits 51% above its 52-week low of $2.645.
Summary
Voyager Therapeutics reported its fourth quarter and full year 2025 financial and operating results, revealing a significant net loss of $119.7 million for the year and a 41% workforce reduction. The company also announced the pausing of its apolipoprotein E (APOE) gene therapy program. This announcement, released just prior to the formal 10-K filing, details substantial financial challenges and a strategic restructuring. While the company emphasized a cash position of $202 million, expected to provide a runway into 2028, and highlighted pipeline progress including anticipated clinical entry for VY1706 and data for VY7523, the large net loss and workforce reduction are material events for a company of this size. Traders will closely watch the execution of the prioritized clinical programs and the company's cash management to sustain its operations.
At the time of this announcement, VYGR was trading at $3.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $228.5M. The 52-week trading range was $2.65 to $5.55. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.